SU6 Stock Overview
Provides performance coating technologies for intravascular medical devices, and chemical and biological components for in vitro diagnostic immunoassay tests and microarrays in the United States and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
No risks detected for SU6 from our risk checks.
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
My Notes
Capture your thoughts, links and company narrative
Surmodics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$26.80 |
| 52 Week High | US$38.80 |
| 52 Week Low | US$23.60 |
| Beta | 1.19 |
| 1 Month Change | -16.77% |
| 3 Month Change | -27.96% |
| 1 Year Change | -3.60% |
| 3 Year Change | -29.84% |
| 5 Year Change | 23.50% |
| Change since IPO | 36.98% |
Recent News & Updates
Recent updates
Shareholder Returns
| SU6 | DE Medical Equipment | DE Market | |
|---|---|---|---|
| 7D | -14.1% | -3.9% | -1.4% |
| 1Y | -3.6% | -14.0% | 15.4% |
Return vs Industry: SU6 exceeded the German Medical Equipment industry which returned -13% over the past year.
Return vs Market: SU6 underperformed the German Market which returned 16.8% over the past year.
Price Volatility
| SU6 volatility | |
|---|---|
| SU6 Average Weekly Movement | 5.0% |
| Medical Equipment Industry Average Movement | 5.5% |
| Market Average Movement | 5.2% |
| 10% most volatile stocks in DE Market | 11.7% |
| 10% least volatile stocks in DE Market | 2.8% |
Stable Share Price: SU6 has not had significant price volatility in the past 3 months compared to the German market.
Volatility Over Time: SU6's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1979 | 389 | Gary Maharaj | www.surmodics.com |
Surmodics, Inc., together with its subsidiaries, provides performance coating technologies for intravascular medical devices, and chemical and biological components for in vitro diagnostic immunoassay tests and microarrays in the United States and internationally. It operates through two segments, Medical Device and In Vitro Diagnostics (IVD). The Medical Device segment engages in the provision of surface modification coating technologies to enhance access, deliverability, and predictable deployment of medical devices; and drug-delivery coating technologies to provide site-specific drug-delivery from the surface of a medical device for neurovascular, peripheral, coronary, and structural heart, and other markets, as well as manufacturing of vascular intervention medical devices, including drug-coated balloons, mechanical thrombectomy devices, and radial access balloon catheters and guide sheaths.
Surmodics, Inc. Fundamentals Summary
| SU6 fundamental statistics | |
|---|---|
| Market cap | €387.75m |
| Earnings (TTM) | -€13.30m |
| Revenue (TTM) | €115.85m |
3.2x
P/S Ratio-27.7x
P/E RatioIs SU6 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| SU6 income statement (TTM) | |
|---|---|
| Revenue | US$125.45m |
| Cost of Revenue | US$31.93m |
| Gross Profit | US$93.52m |
| Other Expenses | US$107.93m |
| Earnings | -US$14.41m |
Last Reported Earnings
Dec 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.01 |
| Gross Margin | 74.55% |
| Net Profit Margin | -11.48% |
| Debt/Equity Ratio | 26.5% |
How did SU6 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/03/10 20:18 |
| End of Day Share Price | 2025/03/10 00:00 |
| Earnings | 2024/12/31 |
| Annual Earnings | 2024/09/30 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Surmodics, Inc. is covered by 12 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| null null | Argus Research Company |
| Daniel Owczarski | Avondale Partners |
| Michael Petusky | Barrington Research Associates, Inc. |